Sixteen Poster Abstracts Reporting The Clinical Effectiveness And Healing Results Of MiMedx Allografts To Be Presented At Desert Foot Conference

MARIETTA, Ga., Nov. 16, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, announced today that 16 poster abstracts chronicling the clinical and cost effectiveness and the accelerated healing results of the Company's dehydrated human amnion/chorion membrane (dHACM) allografts will be presented at the 12^th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona, beginning November 18, 2015, and concluding on November 20, 2015.

Parker H. "Pete" Petit, MiMedx Chairman and CEO, said, "The Desert Foot conference is dedicated to the research and treatment of diabetic foot disorders and lower extremity wounds and surgical applications. In its annual conference, Desert Foot also honors our Federal Services healthcare professionals and the remarkable work they do. MiMedx is extremely proud to be the Grand Sponsor of this year's conference."

MiMedx will also host a symposium presentation entitled, "Clinical Efficacy of EpiFix^® and AmnioFix^® dehydrated human amnion/chorion membrane allografts in Surgical and Wound Care Applications." The symposium will be presented by Christian Bianchi, MD, and Jeffrey Frenchman, DPM, on November 18^th from 8:40 AM until 9:25 AM. Drs. Bianchi and Frenchman are noted Key Opinion Leaders and they will speak on their professional experiences using MiMedx dHACM allografts in the treatment of difficult and extreme wounds. MiMedx will also host a hands-on workshop entitled "Surgical and Wound Care Applications of EpiFix and AmnioFix."  Key Opinion Leaders Patrick Agnew, DPM, Joseph Terebessy, DPM, Laura Heath, DPM, and Matthew Garoufalis, DPM, will present their professional experiences using MiMedx dHACM allografts in the treatment of chronic and complex wounds. The workshop will be presented on November 19^th from 10:15 AM until 1:15 PM.

The 16 poster abstracts present compelling evidence of the clinical effectiveness and the vastly accelerated healing using MiMedx EpiFix and AmnioFix dHACM allografts in the treatment of chronic wounds, difficult lower extremity wounds that have failed prior wound treatment modalities, challenging surgical wounds, wounds threatening the loss of limbs, and other hard-to-heal wounds. The abstracts describe the results of independent case studies undertaken by the presenters. The abstracts include the following:

Desert Foot is the premier Veterans Administration (VA) educational conference for lower extremity / diabetic foot research and treatment with nearly 500 physicians pre-registered to attend this year's conference. The 2015 conference will highlight 58 podium presentations and 110 posters.

MiMedx is exhibiting at the conference in booths #24 and #25.                                       

About EpiFix
EpiFix is a human amniotic allograft tissue offering uniquely processed through the Company's proprietary PURION^® Process. EpiFix dHACM modulates inflammation and reduces scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix minimizes graft waste. EpiFix is a minimally manipulated, dehydrated non-variable cellular amniotic membrane allograft that preserves and delivers multiple extracellular matrix proteins, growth factors, cytokines and other specialty proteins present in amniotic tissue. The Company's PURION Process combines cleaning, dehydration and sterilization, making EpiFix a safe, sterilized tissue that may be stored at ambient conditions for up to 5 years.

About AmnioFix
AmnioFix is a composite amniotic tissue membrane minimally manipulated to protect the collagen matrix and its natural properties. AmnioFix reduces scar tissue formation, modulates inflammation in the surgical site, enhances healing and acts as a barrier. AmnioFix is processed through the proprietary PURION Process that combines cleaning, dehydration and sterilization, and it may be stored at ambient conditions for up to 5 years. The proprietary PURION Process protects the delicate scaffold during processing, leaving an intact collagen matrix. The result is a durable graft with natural barrier properties to optimize surgical performance and ease of use. AmnioFix is available in sheet/membrane, particulate, and wrap configurations. 

About MiMedx
MiMedx^® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies are AmnioFix^®, EpiFix^®, CollaFix™ and OrthoFlo. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane derived from donated placentas. Through our donor program, a mother delivering via scheduled full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION^® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 500,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. The Company has recently introduced OrthoFlo, an amniotic fluid derived allograft for homologous use. Amniotic fluid is donated by consenting mothers delivering healthy babies by scheduled full-term Caesarean section births. CollaFix™, our next technology platform we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.  CollaFix™ is the only biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.

SOURCE MiMedx Group, Inc.

Related Links

http://www.mimedx.com